DUBLIN (Reuters) - Irish drugmaker Elan will return $1 billion to shareholders and seek acquisitions with the proceeds of selling its stake in blockbuster multiple sclerosis (MS) treatment Tysabri to partner Biogen Idec.
via Reuters: Health News Read More Here..
No comments:
Post a Comment